Sector News

Sanofi signs agreement to acquire Kiadis Pharma for $359m

November 6, 2020
Life sciences

Sanofi has signed a definitive agreement to acquire the entire share capital of Kiadis Pharma in a deal valued at approximately €308m ($359m).

Under the agreement, Sanofi will offer €5.45 per share to Kiadis Pharma, a clinical-stage company developing cell-based immunotherapy products.

The acquisition will give Sanofi full control of next-generation natural killer (K-NK) cell platform and pipeline of cell-based cancer immune-therapeutics and infectious disease treatments.

The K-NK cell platform derives from allogeneic or ‘off-the-shelf’ NK cells from a healthy donor and these cells hunt for malignant cancer cells.

It can potentially make products rapidly and economically available for a broad range of indications.

Under the deal, Kiadis will develop NK cell-based medicines alone or with Sanofi’s existing platforms.

Furthermore, the research, development and commercial expertise of Sanofi will be leveraged to advance Kiadis’ pipeline that includes NK cell-based medicines.

Sanofi Research & Development global head John Reed said: “We believe the Kiadis ‘off the shelf’ K-NK cell technology platform will have broad application against liquid and solid tumours, and create synergies with Sanofi’s emerging immuno-oncology pipeline, providing opportunities for us to pursue potential best-in-disease approaches.”

On completion of the public offer, Sanofi will provide the resources and capabilities needed for boosting the development of Kiadis’ programmes.

Kiadis’ pipeline of NK cell therapies includes K-NK002, K-NK003 and KNK-ID-101.

KNK-ID-101 is a programme analysing the properties of K-NK cells and their suitability to fight SARS-CoV-2. It will also analyse whether the cells can be used as a post-exposure pre-emptive therapy for Covid-19 in high-risk patients.

The company anticipates initiating a Phase I / IIa trial evaluating the use of K-NK cells to treat covid-19 patients with government grant funding.

In July, the company licensed Kiadis’ pre-clinical K-NK004 programme for potential combination for multiple myeloma.

by Pharmeceutical-technology.com

Source: pharmaceutical-technology.com

Related News

July 31, 2021

Lonza positions collagen as “key” to future of joint health market

Life sciences

NutritionInsight speaks with Lindsey Toth, associate director of product management at DFS & Ingredients, Lonza Capsules & Health Ingredients.

July 31, 2021

Novo Holdings co-leads Hemab’s US$ 55M Series A to advance next generation therapeutics for bleeding and thrombosis disorders

Life sciences

The company was created in 2020 by Novo Seeds, which worked closely with the founders to develop a commercially attractive business plan to maximise the potential of Hemab’s promising technology platform.

July 31, 2021

BD acquires Tepha to drive new innovations in soft tissue repair and regeneration

Life sciences

BD (Becton, Dickinson and Company) announced today it has acquired Tepha, Inc., a leading developer and manufacturer of a proprietary resorbable polymer technology.

Send this to a friend